Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Generation Masked T-Cell Engager Therapeutics

Collaboration combines Voro’s tumor-activated biologics platform and T-cell engager (TCE) expertise with Alloy’s antibody discovery and TCE engineering capabilities to develop novel tumor-selective immunotherapies

Excerpt from the Press Release:

SAN DIEGO & BOSTON–(BUSINESS WIRE)–Voro Therapeutics, a biotechnology company developing tumor-activated biologics designed to improve the therapeutic index of immune therapies, and Alloy Therapeutics, a biotechnology ecosystem company dedicated to empowering the global biologics community, today announced a strategic research collaboration focused on the discovery and development of next-generation masked T-cell engager (TCE) therapeutics.

The collaboration combines Voro’s proprietary tumor-activated biologics platform and experience in T-cell engager development with Alloy’s optimized CD3 antibodies and multispecific engineering expertise to develop novel immunotherapies designed to selectively activate immune responses within the tumor microenvironment while minimizing activity in healthy tissues.

TCEs have demonstrated significant therapeutic potential across a broad range of cancers but are often limited by systemic toxicities associated with widespread immune activation. Through this collaboration, Voro and Alloy aim to advance novel approaches that may improve the therapeutic index of TCE therapies, potentially enabling broader clinical utility and expanding the reach of immune-based cancer treatments.

“T-cell engagers have shown tremendous promise, but their broader impact has been constrained by the same challenge facing many powerful immune therapies: how to deliver potency without unacceptable systemic toxicity,” said Ugur Eskiocak, Ph.D., Co-Founder and CEO of Voro Therapeutics.

Click the button below to read the entire Press Release:

Continue Reading The Press Release